1 / 21

The Diabetic Retinopathy Clinical Research Network

The Diabetic Retinopathy Clinical Research Network. What is the Role of Laser In Treating Diabetic Macular Edema in the Era of Anti-VEGF Therapy ?. Financial Disclosures. None. 7-6-11. 12-7-11. After 3 Anti-VEGF injections. 2-29-12. After 6 Anti-VEGF injections.

zeno
Télécharger la présentation

The Diabetic Retinopathy Clinical Research Network

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Diabetic Retinopathy Clinical Research Network What is the Role of Laser In Treating Diabetic Macular Edema in the Era of Anti-VEGF Therapy?

  2. Financial Disclosures • None

  3. 7-6-11

  4. 12-7-11 After 3 Anti-VEGF injections

  5. 2-29-12 After 6 Anti-VEGF injections

  6. What should be done next? • Is Laser the next step? • Does it help?

  7. Response to Laserin the ETDRS

  8. ETDRS Data*:Change in VA from Baseline *Of eyes with CI-DME at baseline

  9. Anti-VEGF therapy is now the gold standard for treating diabetic macular edema in eyes with impaired vision. Focal laser is now used for eyes not responding well to Anti-VEGF or eyes where Anti-VEGF is contraindicated. Some doctors use it as the primary treatment in eyes with very focal disease such as a circinate ring.

  10. DRCR.net Protocol I Data(Ranibizumab+prompt laser & Ranibizumab+deferred laser groups)

  11. Visual Acuity

  12. Mean Change in Visual Acuity*at Follow-up Visits N = 338 (52 weeks) N = 317 (104 weeks) N = 291 (156 weeks) *Truncated to ± 30 letters

  13. Change in Visual Acuity* *Visits occurring between 980 and 1204 days from randomization were included as 3 year visits **truncated to ± 30 letters, based on longitudinal analyses adjusting for baseline VA

  14. Retinal Thickening

  15. Mean Change in CSF Thickeningat Follow-up Visits N = 334 (52 weeks) N = 305 (104 weeks) N = 259 (156 weeks)

  16. Change in Retinal Thickening at 3 Years* *Visits occurring between 980 and 1204 days from randomization were included as 3 year visits

  17. Focal/Grid Laser Prior to 3 Years* * Only eyes that completed 3-year visit

  18. DRCR.net New Protocol

  19. Study Objectives • To compare the efficacy and safety of • Anti-VEGF with no laser • Anti-VEGF with deferred laser in eyes with DME. Efficacy will be assessed by change in visual acuity at 1 year. The study will be 2 years in duration. Protocol T Treatment Algorithm 21

More Related